Pazopanib: a novel treatment option for aggressive fibromatosis

Bulut G., Ozluk A., ERDOĞAN A. P., Uslu R., Elmas N., Karaca B.

CLINICAL SARCOMA RESEARCH, cilt.6, ss.1-4, 2016 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 6
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1186/s13569-016-0061-3
  • Dergi Adı: CLINICAL SARCOMA RESEARCH
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI)
  • Sayfa Sayıları: ss.1-4
  • Manisa Celal Bayar Üniversitesi Adresli: Hayır

Özet

Background: Aggressive fibromatosis (AF), also known as desmoid tumor, is an uncommon soft tissue neoplasm. AF does not metastasize, but it is locally invasive and its propensity for recurrence after conservative resection is well documented. No effective cytotoxic treatment has been reported, hence there is a need for novel treatment strategies. Case presentation: We present the case of an AF successfully treated with an oral tyrosine kinase inhibitor, pazopanib, with mild side effects. As far as we know, this is the first case of AF with complete response to pazopanib. Conclusion: Pazopanib might be an effective treatment option for AF.